CSChatrine Sutandi

Chatrine Sutandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chatrine Sutandi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Limb-Body Wall Complex: A rare case report and systematic review

    by Chatrine Sutandi, I Nyoman Hariyasa Sanjaya

    HIGHLIGHTS Evolution from suspected gastroschisis (17+1 weeks) to confirmed LBWC at 20 weeks with classic features (thoracoabdominal wall defect, intestinal malrotation, limb anomalies), aligned with a systematic review of 23 studies (155 cases) showing mainly second-trimester ultrasound diagnosis and uniformly poor prognosis. Early diagnostic pathways (2D/3D ultrasound ± Doppler; adjunct MRI/AFP/genetics) sharpen differentiation from gastroschisis/omphalocele and strengthen evidence for prenatal counseling, management (including termination and delivery planning), and postmortem confirmation. ABSTRACT Objective: To report a rare case of Limb-Body Wall Complex (LBWC) and to synthesize current evidence regarding its diagnostic features, clinical presentation, and outcomes through a structured literature review. Case Report: This study integrates a single case report with a structured review of published cases. A 29-year-old gravida 2 para 0 woman at 20 weeks of gestation presented with absent fetal movement and was diagnosed with intrauterine fetal death accompanied by multiple congenital anomalies. Initial antenatal ultrasound at 17 weeks and 1 day suggested gastroschisis; however, subsequent evaluation confirmed LBWC, characterized by thoracoabdominal wall defect, intestinal malrotation, and limb anomalies. Pregnancy termination was performed using misoprostol, and the fetus was delivered vaginally as a stillbirth. Diagnosis was confirmed macroscopically post-delivery. The literature review, conducted in accordance with PRISMA 2020 guidelines using PEOS criteria, identified 23 eligible studies comprising 155 cases. Most diagnoses were established in the first and second trimesters using ultrasound, with adjunctive imaging or genetic testing in selected cases. Across studies, LBWC consistently demonstrated a uniformly poor prognosis, with outcomes including intrauterine fetal demise, termination of pregnancy, or early neonatal death. Common findings included limb agenesis, scoliosis, short or absent umbilical cord, and organ evisceration. Most included studies were of moderate to high methodological quality. Conclusion: LBWC is a rare and lethal congenital anomaly. Early and accurate antenatal diagnosis, particularly through repeated ultrasound evaluation, is essential to guide clinical decision-making, parental counseling, and pregnancy management

  • Open Access

    Promoter Methylation and Low Placental Expression of Metalloproteinase (MMP)-9, Human Leukocyte Antigen (HLA)-G, Vascular Endothelial Growth Factor (VEGF), and Highly Soluble Endoglin (sEng) as Risk Factors for Preeclampsia

    by Anak Agung Ngurah Jaya Kusuma, I Made Darmayasa, Ni Kadek Mulyantari, Ni Nyoman Wistya Tri Mayasari, Chatrine Sutandi, Godefridus Paulo Bay, Cokorda Gde Angga Ary Nugraha

    BACKGROUND: Dysregulated expressions of metalloproteinase (MMP)-9, human leucocyte antigen (HLA)-G, vascular endothelial growth factor (VEGF), and soluble endoglin (sEng) reflect impaired angiogenesis, immune tolerance, endothelial function, and trophoblast invasion that characterize abnormal placental development in preeclamptic (PE) pregnancies. However, the role of promoter methylation of these markers in linking the pathways to altered protein expression remains unclear. Hence, this study compared promoter methylation and placental expression of MMP-9, HLA-G, VEGF, and sEng between women with PE and normotensive pregnancies, and evaluate their diagnostic performance as potential biomarkers.METHODS: This case–control study included 30 women with PE and 30 controls. Placental tissue samples were collected within 15 minutes postpartum. Placental promoter methylation was assessed using methylation-specific polymerase chain reaction (PCR), and protein expression was measured using enzyme-linked immunosorbent assay (ELISA). Group differences were analyzed, diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves, and associations were expressed as adjusted odds ratios (AOR).RESULTS: Compared with controls, placentas from women with PE significantly showed higher methylation of HLA-G (58.9% vs. 37.3%) and sEng (6.7% vs. 4.1%), and lower methylation of VEGF (30.4% vs. 48.1%) and MMP-9 (36.1% vs. 44.9%). Expression of MMP-9, HLA-G, and VEGF was significantly reduced, while sEng expression was increased in PE. Multivariate analysis identified HLA-G hypermethylation (AOR 5.36), VEGF hypomethylation (AOR 8.55), sEng methylation (AOR 4.57), low expression of MMP-9, HLA-G, and VEGF, and high sEng expression (AOR 4.77) as independent predictors of PE. sEng expression demonstrated the best discrimination (AUC 0.835), followed by sEng methylation (AUC 0.785) and HLA-G methylation (AUC 0.774).CONCLUSION: PE is associated with distinct placental methylation–expression alterations, with sEng- and HLA-G–related markers showing the strongest diagnostic value.KEYWORDS: preeclampsia, DNA methylation, angiogenesis, MMP-9, HLA-G, sEng, placenta, epigenetics